What Is RETA (Retatrutide)?
RETA, known scientifically as Retatrutide, is a next-generation triple receptor agonist that simultaneously targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple mechanism of action places it at the very frontier of metabolic peptide research.
Mechanism of Action
Retatrutide's triple agonism works across three complementary pathways. GLP-1 receptor activation reduces appetite and slows gastric emptying. GIP receptor activation enhances insulin sensitivity and amplifies GLP-1 effects. Glucagon receptor activation increases energy expenditure and promotes fat oxidation in the liver.
What Research Shows
Early-phase clinical research on Retatrutide has produced remarkable data. Studies have reported substantial reductions in body weight — among the highest observed for any pharmacological compound in obesity research to date. Additionally, research has shown improvements in liver fat, triglycerides, blood pressure, and fasting glucose.
Research Applications
- Severe obesity and body composition research
- Non-alcoholic steatohepatitis (NASH) and liver fat studies
- Triple incretin pharmacology
- Energy expenditure and thermogenesis research
- Cardiometabolic risk factor investigation
Freeze-Dried Format
Our RETA is available in lyophilised (freeze-dried) powder form, preserving full peptide integrity for research use.
Important Disclaimer
This compound is intended strictly for research purposes only. It is not approved for human consumption and is not intended to diagnose, treat, cure, or prevent any disease.
🛒 Shop This Compound
RETA is available as part of our Metabo GLP-3 Peptide collection at SONOCOUTURE.